medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2013, Number 4

<< Back

Rev Mex Angiol 2013; 41 (4)

Trombosis arterial digital en mano secundaria a trombocitemia esencial

Lara-Guerrero MI, Vélez-Lomana A, Fustero-Aznar JM, Hermoso-Cuenca V

Language: Spanish
References: 11
Page: 232-235
PDF size: 206.91 Kb.


ABSTRACT

Essential thrombocythemia (ET) is a myeloproliferative neoplasm classical Philadelphia chromosome- negative consisting of an increase in the production of platelets. The clinical diagnosis requires exclusion of other causes of myeloproliferative disorders and reactive thrombocytosis. The ET is a rare disorder, with an incidence of 1-3 cases/100,000 hab/year, being more frequent in women (60%) and in the 5th-6th decade of life, although 15-20% of patients are under 40 years old. The cause is unknown, being an acquired disorder, the 23-57% of patients presenting mutation JAK2-V617F. While most patients are asymptomatic, ET increases the risk of thrombohemorrhagic complications. Cytoreduction and inhibitor platelet pharmacologic therapy prevent complications of thrombosis. We report a patient with an infarction digital in the fingers of the hand during the treatment of essential thrombocythemia.


REFERENCES

  1. Major Vascular Complications in Essential Thrombocythemia: a Study of the Predictive Factors in a series of 148 patients. Leukemia 1999; 13: 150-4.

  2. Harrison CN, Campbell PJ, Buck G, Wheatly K, Bareford D, Wilkins BS, Van der Walt JD, et al. Hydroxyurea Compared with Anagrelide in High-risk Essential Thrombocythemia. N Engl J Med 2005; 353: 33-45.

  3. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrmbotic and Hemarrhagic Complications in Essential Thrombocythemia. A Retrospective Study of 103 Patients. Cancer 1991; 67: 2926-30.

  4. Oki M, Moriuchi M, Kawada H, et al. A case of essential thrombocythemia presenting with aortic thrombosis. Tokai J Exp Clin Med 2008; 33(4): 135-7.

  5. Harrison C, Path MRC, Campbell PJ, et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N Engl J Med 2005; 353: 33-45.

  6. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. J Clin Oncol 2008; 26: 2732-36.

  7. Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol 2002; 29: 10-5.

  8. Hon J, Chow S, Abadía S, et al. Myeloproliferative disorder as the cause of peripheral ischemia in a young patient. Ann Vasc Surg 2008; 22: 456-8.

  9. Lee HS, Park LC, Lee EM, et al. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leuk 2012; 12(1): 70-5.

  10. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117(22): 5857-9.

  11. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-Negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011. DOI:10.1200/ JCO.2010.31.8436.




2020     |     www.medigraphic.com